Fundraising Fox

Biolexis Therapeutics

Lehi, US · Founded 2021 · Delaware corporation

Find your way into Biolexis Therapeutics

Biotech

Founders & leadership

Biolexis Therapeutics was founded in 2021 by David J. Bearss.

DJDavid J. Bearss
David J. BearssinFounderDavid J. Bearss is a director and co-founder of Biolexis Therapeutics, whose platform combines computational chemistry, machine learning, and metabolic biology to develop GLP-1 receptor positive allosteric modulators and AMPK activators for cardiometabolic disease. He has over two decades of experience in disease biology and medicinal chemistry, is a named inventor on 80+ patent filings across oncology, inflammation, neurodegeneration, and precision medicine, and also leads drug discovery and development at Halia Therapeutics.
TH
Tyler HartmanninExecutive
DT
David TaylorChief Financial Officer and Secretary
HV
Hariprasad VankayalapatiNamed on SEC filing

Board

JN
James N. ClarkeBoard director
AS
Anthony SteveBoard director

Reported raises · per SEC filings

Form D private placements

$6.3M disclosed across 5 rounds · 2022–2026

▶$1.6MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tyler HartmannExecutive Officer
  • Hariprasad VankayalapatiDirector
  • James N. ClarkeDirector
  • Anthony SteveDirector
  • David J. BearssDirector
Offering amount
$12M
Amount sold
$1.6M
First sale
May 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. Hariprasad VankayalapatiExecutive Officer, Director
  • David O. TaylorExecutive Officer, Director
  • Dr. David J. BearssExecutive Officer, Director
Amount sold
$1M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$725KraisedOct 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David O. TaylorExecutive Officer, Director
  • Dr. Hariprasad VankayalapatiExecutive Officer, Director
  • Dr. David J. BearssExecutive Officer, Director
Offering amount
$725K
Amount sold
$725K
First sale
Sep 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedSep 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. Hariprasad VankayalapatiExecutive Officer
  • Dr. David J. BearssExecutive Officer
  • David O. TaylorExecutive Officer
Amount sold
$1.5M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedMar 2022 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hariprasad VankayalapatiExecutive Officer, Director
  • David TaylorExecutive Officer
  • David J. BearssExecutive Officer
Offering amount
$2M
Amount sold
$1.5M
First sale
Feb 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Biolexis: AI-Driven Drug Discovery Company Secures $10 Millionpulse2.com · Dec 2023Biolexis secures $10 million in Series A funding to advance metabolic drug development – Utah Businessutahbusiness.com · Nov 2023

Frequently asked questions

Who founded Biolexis Therapeutics?
Biolexis Therapeutics was founded by David J. Bearss in 2021.
How much funding has Biolexis Therapeutics raised?
Biolexis Therapeutics has disclosed $6.3M raised across 5 rounds.
Where is Biolexis Therapeutics headquartered?
Biolexis Therapeutics is headquartered in Lehi, US.